연구동향 분석

Effects of Recombinant Phage lysin SAL200 in Combination with antibiotics on Staphylococcal biofilm = 포도알균 생막에서 재조합 파지 SAL200의 항생제 병합 효과

장미옥 2020년

논문상세정보
인용/피인용
' Effects of Recombinant Phage lysin SAL200 in Combination with antibiotics on Staphylococcal biofilm = 포도알균 생막에서 재조합 파지 SAL200의 항생제 병합 효과' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 의료과학 약
  • SAL200
  • antistaphylococcal antibiotics
  • bacteriophage
  • biofilm
  • combination
  • lysin
  • mrsa
  • staphylococci
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
4,214 0

0.0%

' Effects of Recombinant Phage lysin SAL200 in Combination with antibiotics on Staphylococcal biofilm = 포도알균 생막에서 재조합 파지 SAL200의 항생제 병합 효과' 의 참고문헌

  • Wittekind M : Bacteriophage Lysin CF-301 , a Potent Antistaphylococcal Biofilm Agent .
    61 ( 7 ) : e02666-16 . [2017]
  • The challenge of treating biofilm-associated bacterial infections
    82 ( 2 ) :204-209 [2007]
  • Revisiting phage therapy : New applications for old resources
    23 ( 4 ) :185-191 . [2015]
  • Quantification of biofilm in microtiter plates : overview of testingConditions and practical recommendations for assessment of biofilm production by staphylococci
    115 ( 8 ) :891-899 [2007]
  • Preclinical safety evaluation of intravenously administered SAL200Containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient .
    58 ( 4 ) :2084-2088 . [2014]
  • Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a single intravenous administration among healthy volunteers
    61 : e02629-16 [2017]
  • New Innovations in the Treatment of PJI and Biofilms-Clinical and Preclinical Topics
    11 ( 3 ) :380-388 . [2018]
  • Monitoring bioluminescent Staphylococcus aureus infections in living mice using a novel luxABCDE construct
    68 ( 6 ) :3594-3600 . [2000]
  • Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus
    73 ( 1 ) :347-352 [2007]
  • Lysins : the arrival of pathogen-directed anti-infectives .
    62 ( Pt 10 ) :1506-1516 . [2013]
  • Kozitskaya S : Nosocomial infections by Staphylococcus epidermidis : how a commensal bacterium turns into a pathogen .
    28 Suppl 1 : S14-20 . [2006]
  • Kokai-Kun JF : Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces
    47 ( 11 ) :3407-3414 . [2003]
  • Incidence , prevalence , and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment
    21 ( 1 ) :211 . [2017]
  • In vitro activity of tedizolid against staphylococci isolated from prosthetic joint infections
    85 ( 1 ) :77-79 [2016]
  • Horz HP : Fighting Pathogenic Bacteria on Two Fronts : Phages and Antibiotics as Combined Strategy
    0.390277777777778 [2019]
  • Fischetti VA : Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus
    54 ( 4 ) :1603-1612 . [2010]
  • Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats
    63 ( 10 ) : e01235-19 . [2019]
  • Emerging antibiotic-resistant bacteria . Their treatment in total joint arthroplasty .
    369:110-123 [1999]
  • Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years
    66 ( 4 ) :441-444 . [2010]
  • Effects of Phage Endolysin SAL200 Combined with Antibiotics on Staphylococcus aureus Infection
    62 ( 10 ) . [2018]
  • Effective removal of staphylococcal biofilms by the endolysin LysH5 .
    9 ( 9 ) : e107307 . [2014]
  • Degradation of methicillin-resistant Staphylococcus aureus biofilms using a chimeric lysin
    30 ( 6 ) :667-674 . [2014]
  • Cotherapy using lytic bacteriophage and linezolid : effective treatment in eliminating methicillin resistant Staphylococcus aureus ( MRSA ) from diabetic foot infections
    8 ( 2 ) : e56022 . [2013]
  • Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK
    55 ( 4 ) :1764-1767 . [2011]
  • Clinical microbiology procedures handbook
    vol 2. [2010]
  • Characterization of the importance of polysaccharide intercellular adhesin/hemagglutinin of Staphylococcus epidermidis in the pathogenesis of biomaterial-based infection in a mouse foreign body infection model
    67 ( 5 ) :2627-2632 . [1999]
  • Characterization of induced Staphylococcus aureus bacteriophage SAP-26 and its anti-biofilm activity with rifampicin
    27 ( 10 ) :1087-1093 . [2011]
  • Candida albicans biofilm formation in a new in vivo rat model
    156 ( Pt 3 ) :909-919 . [2010]
  • Are Phage Lytic Proteins the Secret Weapon To Kill Staphylococcus aureus ?
    9 ( 1 ) . [2018]
  • Antibacterial properties of a pre-formulated recombinant phage endolysin , SAL-1
    41 ( 2 ) :156-161 . [2013]
  • Activity of Tedizolid in Methicillin-Resistant Staphylococcus epidermidis Experimental Foreign Body-Associated Osteomyelitis
    61 ( 2 ) : e01644-16 . [2017]
  • A new colorimetric microtitre model for the detection of Staphylococcus aureus biofilms
    46 ( 2 ) :249-254 [2008]
  • A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms
    57 ( 6 ) :2726-2737 . [2013]
  • 3. Otto M: Staphylococcal biofilms. Curr Top Microbiol Immunol 2008, 322:207-228.
    322:207-228 [2008]
  • 29. Tallarida RJ: Revisiting the isobole and related quantitative methods for assessing drug synergism. J Pharmacol Exp Ther 2012, 342(1):2-8.
  • 23. Institute CaLS: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-tenth edition. In: CLSI document M07-A10. vol. Wayne, PA; 2015.
  • 22. Institute CaLS: Performance standards for antimicrobial susceptibility testing; Twenty-Fifth Informational Supplement M100-S25. MBBC of SAL200 was lower than vancomycin, nafcillin and linezolid.
  • 20. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing; Twenty-Fifth Informational Supplement M100-S25. Clinical and Laboratory Standards Institute. Wayne, PA; 2015.
  • 2. Lowy FD: Staphylococcus aureus infections. N Engl J Med 1998, 339(8):520-532.